T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ExxonMobil
XOM
|
+$1.76B |
| 2 |
Eli Lilly
LLY
|
+$1.4B |
| 3 |
Bank of America
BAC
|
+$1.3B |
| 4 |
Tesla
TSLA
|
+$1.19B |
| 5 |
Wells Fargo
WFC
|
+$784M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$6.47B |
| 2 |
Amazon
AMZN
|
+$3.71B |
| 3 |
Yum! Brands
YUM
|
+$2.84B |
| 4 |
Salesforce
CRM
|
+$2.77B |
| 5 |
Fortive
FTV
|
+$2.41B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.06% |
| 2 | Healthcare | 18.72% |
| 3 | Consumer Discretionary | 14.62% |
| 4 | Financials | 10.36% |
| 5 | Communication Services | 9.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VBTX
2151
DELISTED
Veritex Holdings
VBTX
| $467K | ﹤0.01% |
17,528
-2,624,266
| -99% | -$79.4M |
|
2152
Lexicon Pharmaceuticals
LXRX
$1.05B
| $464K | ﹤0.01% |
193,275
-4,166
| -2% | -$11.5K |
|
2153
Artivion
AORT
$1.39B
| $462K | ﹤0.01% |
33,317
+2,369
| +8% | +$47.7K |
|
2154
Ingles Markets
IMKTA
$1.66B
| $460K | ﹤0.01% |
5,801
+933
| +19% | +$84.8K |
|
2155
Healthcare Services Group
HCSG
$1.43B
| $459K | ﹤0.01% |
37,926
+7,128
| +23% | +$105K |
|
2156
iShares S&P 500 Growth ETF
IVW
$77.9B
| $459K | ﹤0.01% |
+7,930
| New | +$515K |
|
2157
The RMR Group
RMR
$337M
| $459K | ﹤0.01% |
19,334
+4,327
| +29% | +$118K |
|
2158
Acco Brands
ACCO
$399M
| $458K | ﹤0.01% |
93,468
-31,645
| -25% | -$200K |
|
2159
FIGS
FIGS
$2.4B
| $457K | ﹤0.01% |
55,360
-4,007,434
| -99% | -$42.6M |
|
2160
NETGEAR
NTGR
$658M
| $457K | ﹤0.01% |
22,794
+1,669
| +8% | +$37.5K |
|
2161
Veru
VERU
$46.7M
| $456K | ﹤0.01% |
3,953
-4,125
| -51% | -$595K |
|
|
HSII
2162
DELISTED
Heidrick & Struggles
HSII
| $450K | ﹤0.01% |
17,290
+1,953
| +13% | +$57.7K |
|
2163
Embecta
EMBC
$269M
| $446K | ﹤0.01% |
15,478
-3,125,788
| -100% | -$92.5M |
|
2164
Senseonics Holdings Inc
SENS
$419M
| $446K | ﹤0.01% |
16,872
+1,402
| +9% | +$42.9K |
|
|
QVCGA
2165
DELISTED
QVC Group Inc Series A
QVCGA
| $446K | ﹤0.01% |
4,437
+588
| +15% | +$85.2K |
|
|
RFP
2166
DELISTED
Resolute Forest Products Inc.
RFP
| $446K | ﹤0.01% |
22,260
+3,376
| +18% | +$67.8K |
|
2167
Revolve Group
RVLV
$1.69B
| $445K | ﹤0.01% |
20,492
+4,797
| +31% | +$126K |
|
|
NGM
2168
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $445K | ﹤0.01% |
33,945
+13,505
| +66% | +$205K |
|
|
SGFY
2169
DELISTED
Signify Health, Inc.
SGFY
| $445K | ﹤0.01% |
15,254
+1,688
| +12% | +$38.9K |
|
2170
Franklin Covey
FC
$234M
| $444K | ﹤0.01% |
9,776
-2,635
| -21% | -$130K |
|
2171
Titan International
TWI
$450M
| $444K | ﹤0.01% |
36,526
+7,814
| +27% | +$112K |
|
2172
Collegium Pharmaceutical
COLL
$913M
| $443K | ﹤0.01% |
27,592
+2,012
| +8% | +$35.5K |
|
2173
Unitil
UTL
$984M
| $443K | ﹤0.01% |
9,525
-698
| -7% | -$37.8K |
|
|
HAYN
2174
DELISTED
Haynes International, Inc.
HAYN
| $443K | ﹤0.01% |
12,612
-1,509,868
| -99% | -$57M |
|
|
EHAB
2175
DELISTED
Enhabit
EHAB
| $442K | ﹤0.01% |
+31,417
| New | +$509K |
|
Similar funds
T. Rowe Price Associates's Q3 2022 Portfolio in Review
As of Q3 2022, T. Rowe Price Associates held 3,114 positions worth $610B, down 23% from $791B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
T. Rowe Price Associates withdrew a net $168B in Q3 2022, closing 171 positions and reducing 1,248 holdings. Its most notable exit was Alcon, an estimated $1.51B position sold in full.
By sector, the portfolio is most concentrated in Technology at 26% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, T. Rowe Price Associates opened a new position in Corebridge Financial worth $194M.
- T. Rowe Price Associates's largest Q3 2022 buy was Corebridge Financial: 9,831,688 shares worth $194M.
- T. Rowe Price Associates added most to ExxonMobil in Q3 2022, an estimated $1.76B increase.
- T. Rowe Price Associates's biggest Q3 2022 reduction was Microsoft, cutting an estimated $6.47B.
- T. Rowe Price Associates fully exited Alcon in Q3 2022, selling an estimated $1.51B.
- T. Rowe Price Associates's ten largest holdings make up 31% of its $610B portfolio in Q3 2022.
- T. Rowe Price Associates opened 154 new positions and closed 171 in Q3 2022.
- T. Rowe Price Associates's portfolio value fell 23% quarter-over-quarter to $610B.
Based on T. Rowe Price Associates's 13F filing for Q3 2022, filed 14 Nov 2022.